Acurx Pharmaceuticals (ACXP) News Today → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free ACXP Stock Alerts $2.40 +0.03 (+1.27%) (As of 06/7/2024 06:55 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call TranscriptMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid FinancialsMay 16, 2024 | insidermonkey.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comAcurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...May 16, 2024 | finance.yahoo.comQ1 2024 Acurx Pharmaceuticals Inc Earnings CallMay 15, 2024 | morningstar.comAcurx Pharmaceuticals Inc Ordinary SharesMay 15, 2024 | msn.comAcurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04May 15, 2024 | prnewswire.comAcurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionMay 15, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdateMay 2, 2024 | finance.yahoo.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceMay 2, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceApril 25, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceApril 23, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business UpdateApril 17, 2024 | nasdaq.comAcurx Pharmaceuticals Rings the Closing BellMarch 20, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | markets.businessinsider.comAcurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic PartnershipsMarch 19, 2024 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.comQ4 2023 Acurx Pharmaceuticals Inc Earnings CallMarch 18, 2024 | investorplace.comACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023March 18, 2024 | finance.yahoo.comWe Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth CarefullyMarch 18, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 4, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business UpdateFebruary 27, 2024 | finance.yahoo.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 27, 2024 | prnewswire.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 17, 2024 | finance.yahoo.comACXP Mar 2024 4.000 callFebruary 16, 2024 | finance.yahoo.comACXP Mar 2024 5.000 putFebruary 2, 2024 | finance.yahoo.comNew to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PTFebruary 1, 2024 | finance.yahoo.comNew to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PTJanuary 26, 2024 | finance.yahoo.comNew to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PTJanuary 23, 2024 | finance.yahoo.comAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024January 17, 2024 | msn.comAcurx stock plunges 26% amid Phase 2 data release for C. diff drugJanuary 17, 2024 | msn.comELAB, KIND and RLX among pre-market losersJanuary 17, 2024 | markets.businessinsider.comAcurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b TrialJanuary 5, 2024 | finance.yahoo.comNew to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PTJanuary 3, 2024 | finance.yahoo.comAcurx to present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 28, 2023 | benzinga.comAcurx Pharmaceuticals Stock (NASDAQ:ACXP), Guidance and ForecastDecember 15, 2023 | markets.businessinsider.comImpressive Phase 2b Results and Positive Outlook Justify Buy Rating for Acurx PharmaceuticalsDecember 13, 2023 | markets.businessinsider.comBuy Rating for Acurx Pharmaceuticals Stemming from Ibezapolstat’s Positive Phase 2b ResultsDecember 11, 2023 | msn.comWhy Acurx Pharmaceuticals (ACXP) Shares Are Falling TodayDecember 7, 2023 | finance.yahoo.comNew to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PTNovember 24, 2023 | finance.yahoo.comNew to The Street Announces its Five Business Guest Interviews, Episode 533, Airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PTNovember 17, 2023 | finance.yahoo.comNew to The Street Announces Episode 530 with Six Corporate Interviews, Airing on the Fox Business Network, Monday, November 20, 2023, at 10:30 PM PTNovember 15, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | benzinga.comAcurx Pharmaceuticals: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.com12 Best Day Trading Stocks To BuyNovember 3, 2023 | markets.businessinsider.comBuy Rating on Acurx Pharmaceuticals: Promising Clinical Results and Financial Stability Highlighted by Analyst Ed ArceNovember 2, 2023 | msn.comAcurx Pharma falls after mid-stage data for lead assetNovember 2, 2023 | msn.comAcurx Pharmaceuticals (ACXP) Price Target Increased by 8.82% to 12.58November 2, 2023 | finance.yahoo.comAcurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Executive Order To Wipe Out Your Bank Accounts (Ad)Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast. Click Here To Get Your FREE Guide Now! ACXP Media Mentions By Week ACXP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACXP News Sentiment▼0.000.77▲Average Medical News Sentiment ACXP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACXP Articles This Week▼01▲ACXP Articles Average Week Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Indaptus Therapeutics News Aytu BioPharma News Werewolf Therapeutics News Sagimet Biosciences News I-Mab News Repare Therapeutics News Veru News scPharmaceuticals News Regulus Therapeutics News Syros Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACXP) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored